ECSP23027106A - Formulación combinada oral que incluye gemigliptina y dapagliflozina y método de preparación para la misma - Google Patents

Formulación combinada oral que incluye gemigliptina y dapagliflozina y método de preparación para la misma

Info

Publication number
ECSP23027106A
ECSP23027106A ECSENADI202327106A ECDI202327106A ECSP23027106A EC SP23027106 A ECSP23027106 A EC SP23027106A EC SENADI202327106 A ECSENADI202327106 A EC SENADI202327106A EC DI202327106 A ECDI202327106 A EC DI202327106A EC SP23027106 A ECSP23027106 A EC SP23027106A
Authority
EC
Ecuador
Prior art keywords
gemigliptin
dapagliflozin
preparation
formulation including
oral formulation
Prior art date
Application number
ECSENADI202327106A
Other languages
English (en)
Spanish (es)
Inventor
Myeong Hyeon Park
Dong Min Kim
Jae Soon Ahn
Joo Myung Jang
Sun Lee
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of ECSP23027106A publication Critical patent/ECSP23027106A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ECSENADI202327106A 2020-10-13 2023-04-13 Formulación combinada oral que incluye gemigliptina y dapagliflozina y método de preparación para la misma ECSP23027106A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20200131868 2020-10-13

Publications (1)

Publication Number Publication Date
ECSP23027106A true ECSP23027106A (es) 2023-05-31

Family

ID=81208465

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202327106A ECSP23027106A (es) 2020-10-13 2023-04-13 Formulación combinada oral que incluye gemigliptina y dapagliflozina y método de preparación para la misma

Country Status (10)

Country Link
KR (1) KR20220048952A (zh)
CL (1) CL2023001014A1 (zh)
CO (1) CO2023006028A2 (zh)
CR (1) CR20230161A (zh)
DO (1) DOP2023000071A (zh)
EC (1) ECSP23027106A (zh)
MX (1) MX2023004218A (zh)
PE (1) PE20231943A1 (zh)
TW (1) TWI826841B (zh)
WO (1) WO2022080815A1 (zh)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180058510A (ko) * 2016-11-24 2018-06-01 한미약품 주식회사 다파글리플로진 l-프롤린을 포함하는 약제학적 제제
WO2018124497A1 (ko) * 2016-12-30 2018-07-05 한미약품 주식회사 다파글리플로진 l-프롤린과 항당뇨병제를 포함하는 약제학적 복합 제제
KR20180078762A (ko) * 2016-12-30 2018-07-10 한미약품 주식회사 다파글리플로진 l-프롤린을 포함하는 당뇨병 질환의 예방 또는 치료용 약제학적 조성물
KR102204439B1 (ko) 2018-05-14 2021-01-18 에이치케이이노엔 주식회사 Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
PE20231943A1 (es) 2023-12-05
CL2023001014A1 (es) 2023-12-11
KR20220048952A (ko) 2022-04-20
MX2023004218A (es) 2023-04-21
DOP2023000071A (es) 2023-07-09
TWI826841B (zh) 2023-12-21
CR20230161A (es) 2023-09-21
CO2023006028A2 (es) 2023-07-10
TW202228701A (zh) 2022-08-01
WO2022080815A1 (ko) 2022-04-21

Similar Documents

Publication Publication Date Title
MX2022011804A (es) Uso de agentes para el tratamiento de condiciones respiratorias.
BRPI0816317A2 (pt) Método para tratar o estresse oxidativo e melhorar a memória de trabalho pela administração de pterostilbeno
BR112012006010A2 (pt) composto de glicina
UA105644C2 (uk) Способи лікування легеневих порушень складами ліпосомального амікацину
BRPI0414347A (pt) associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
WO2020076760A3 (en) Sphingoid compounds for use in the prophylaxis and/or therapy of a viral infection
CO6280474A2 (es) Composicion farmaceutica para el tratamiento de la eyaculacion precoz
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2023001671A (es) Procedimiento y compuesto para su uso en el tratamiento y/o prevención de la netosis.
CL2022000781A1 (es) Tratamientos cognitivos medicinales
MX2021009219A (es) Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria.
BR112023021131A2 (pt) Tratamento de tremor essencial
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
ECSP23027106A (es) Formulación combinada oral que incluye gemigliptina y dapagliflozina y método de preparación para la misma
AR045423A1 (es) Combinaciones de analiticos y antidepresivos
BR112021019779A2 (pt) Novo composto e composição para prevenção ou tratamento de doenças respiratórias compreendendo os mesmos como ingrediente ativo
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
CL2022000320A1 (es) Compuestos adecuados para el tratamiento y la profilaxis del desgaste muscular y otras afecciones
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2023011297A (es) Antagonista del dominio de alfa/beta hidrolasa 6 (abhd6).
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
JP5880913B2 (ja) パーキンソン病の体幹症状（姿勢反射異常）の治療剤